HomeCompareARCC vs PKI

ARCC vs PKI: Dividend Comparison 2026

ARCC yields 10.82% · PKI yields 0.24%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARCC wins by $4.8K in total portfolio value
10 years
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →
PKI
PKI
● Live price
0.24%
Share price
$115.24
Annual div
$0.28
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.7K
Annual income
$0.02
Full PKI calculator →

Portfolio growth — ARCC vs PKI

📍 ARCC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARCCPKI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARCC + PKI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ARCC pays
PKI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
PKI
Annual income on $10K today (after 15% tax)
$20.65/yr
After 10yr DRIP, annual income (after tax)
$0.02/yr
At 15% tax rate, ARCC beats the other by $0.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARCC + PKI for your $10,000?

ARCC: 50%PKI: 50%
100% PKI50/50100% ARCC
Portfolio after 10yr
$22.1K
Annual income
$0.59/yr
Blended yield
0.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
PKI
Analyst Ratings
13
Buy
18
Hold
Consensus: Hold
Price Target
$166.57
+44.5% upside vs current
Range: $145.00 — $202.00
Altman Z
2.9
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARCC buys
0
PKI buys
0
No recent congressional trades found for ARCC or PKI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARCCPKI
Forward yield10.82%0.24%
Annual dividend / share$1.92$0.28
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%-50%
Portfolio after 10y$24.5K$19.7K
Annual income after 10y$1.16$0.02
Total dividends collected$1.1K$24.00
Payment frequencyquarterlyquarterly
SectorBDCStock
Analyst consensusBuyHold
Analyst price target$21.88$166.57

Year-by-year: ARCC vs PKI ($10,000, DRIP)

YearARCC PortfolioARCC Income/yrPKI PortfolioPKI Income/yrGap
1← crossover$11,381$541.15$10,712$12.15+$669.00ARCC
2$12,621$284.08$11,468$6.08+$1.2KARCC
3$13,827$145.31$12,274$3.04+$1.6KARCC
4$15,062$73.43$13,135$1.52+$1.9KARCC
5$16,364$36.89$14,055$0.76+$2.3KARCC
6$17,757$18.49$15,039$0.38+$2.7KARCC
7$19,258$9.25$16,092$0.19+$3.2KARCC
8$20,880$4.63$17,218$0.10+$3.7KARCC
9$22,636$2.32$18,424$0.05+$4.2KARCC
10$24,539$1.16$19,713$0.02+$4.8KARCC

ARCC vs PKI: Complete Analysis 2026

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →

PKIStock

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Full PKI Calculator →
📬

Get this ARCC vs PKI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARCC vs MAINARCC vs HTGCARCC vs GBDCARCC vs ORCCARCC vs BXSLARCC vs SCHDARCC vs JEPIARCC vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.